News & Updates

For patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), initiation of Janus kinase (JAK) inhibitor treatment does not carry a higher short-term risk of cancer, with the exception of nonmelanoma skin cancer (NMSC), as compared with initiation of biological disease-modifying antirheumatic drugs (bDMARDs) including tumour necrosis factor (TNF) inhibitors, according to a study.

The addition of the antipsychotic drug aripiprazole to current antidepressant medications may help improve the symptoms of clinical depression in older adults who have not responded to standard treatments, as reported in a study.

Use of antihypertensive agents that modify the renin-angiotensin system (RAS) helps lower the risk of cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE), suggests a study.

In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.

Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.

Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.